eFFECTOR Therapeutics (eFFECTOR Therapeutics) Earnings Yield (Joel Greenblatt) % : -88.50% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Earnings Yield (Joel Greenblatt) %?

eFFECTOR Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $37.03 Mil. eFFECTOR Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-32.89 Mil. eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -88.50%.

The historical rank and industry rank for eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

EFTR' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -785.27 Med: 29.43 Max: 1158.69
Current: -370.37

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of eFFECTOR Therapeutics was 1158.69%. The lowest was -785.27%. And the median was 29.43%.

EFTR's Earnings Yield (Joel Greenblatt) % is ranked worse than
94.33% of 1394 companies
in the Biotechnology industry
Industry Median: -15.44 vs EFTR: -370.37

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. eFFECTOR Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

eFFECTOR Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Earnings Yield (Joel Greenblatt) % Chart

eFFECTOR Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Earnings Yield (Joel Greenblatt) %

5.76

-172.41

-88.50

eFFECTOR Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings Yield (Joel Greenblatt) %	Get a 7-Day Free Trial									-172.41	-204.08	-74.63	-82.64	-88.50

Competitive Comparison of eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.

eFFECTOR Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

eFFECTOR Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)	=	EBIT	/	Enterprise Value
	=	-32.892	/	37.0276158
	=	-88.83 %

eFFECTOR Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.89 Mil.

eFFECTOR Therapeutics (NAS:EFTR) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.

Be Aware

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.

eFFECTOR Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

eFFECTOR Therapeutics (eFFECTOR Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (NAS:EFTR) » Definitions » Earnings Yield (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

LWK:Germany LWK:Germany

Address

142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075

Website

https://www.effector.com

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Executives

Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich	director, 10 percent owner, officer: Chief Executive Officer	499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi	officer: Chief Business Officer	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner	officer: Chief Medical Officer	C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc	10 percent owner	2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc	10 percent owner	1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc	10 percent owner	C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c.	10 percent owner	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr.	director, 10 percent owner	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland	director, officer: President and Chief Executive	9050 CAMINO SANTA FE, SAN DIEGO CA 92121